Journal
CANCER CELL
Volume 34, Issue 3, Pages 453-+Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2018.08.006
Keywords
-
Categories
Funding
- European Institute of Oncology (IEO)
- Italian Association for Cancer Research (AIRC)
- NIH [R35CA-210105, R01CA172492]
- Herbert Irving Comprehensive Cancer Center (HICCC) Flow Core Facility [P30CA013696]
Ask authors/readers for more resources
The gene encoding the MEF2B transcription factor is mutated in germinal center (GC)-derived B cell lymphomas, but its role in GC development and lymphomagenesis is unknown. We demonstrate that Mef2b deletion reduces GC formation in mice and identify MEF2B transcriptional targets in GC, with roles in cell proliferation, apoptosis, GC confinement, and differentiation. The most common lymphoma-associated MEF2B mutant (MEF2B(D83V)) is hypomorphic, yet escapes binding and negative regulation by components of the HUCA complex and class IIa HDACs. Mef2b(D83V) expression in mice leads to GC enlargement and lymphoma development, a phenotype that becomes fully penetrant in combination with BCL2 de-regulation, an event associated with human MEF2B mutations. These results identify MEF2B as a critical GC regulator and a driver oncogene in lymphomagenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available